Software

Scientists in the Broad community have developed many critical software tools for the analysis of increasingly large genome-related datasets, and they make these tools openly available to the scientific community. For the conditions governing the use of Broad Institute software, please see the software use agreement associated with the tools you choose to download.

Use our search function, browse the complete software collection or click on one of the software categories listed below:

  • Broad-Novartis Cancer Cell Line Encyclopedia (CCLE)

    The Cancer Cell Line Encyclopedia (CCLE) project is a collaboration between the Broad Institute, and the Novartis Institutes for Biomedical Research and its Genomics Institute of the Novartis Research Foundation to conduct a detailed genetic and pharmacologic characterization of a large panel of human cancer models, to develop integrated computational analyses that link distinct pharmacologic vulnerabilities to genomic patterns and to translate cell line integrative genomics into cancer patient stratification. The CCLE provides public access analysis and visualization of DNA copy number, mRNA expression and mutation data for about 1000 cell lines. 

  • Cancer Therapeutics Response Portal

    The Cancer Therapeutics Response Portal enables analyses a genomic cancer cell-line profiling to identify more comprehensively relationships between genetic and lineage features of human cancer cell lines and small-molecule sensitivity.

  • ChemBank

    ChemBank is the flagship project of the Chemical Biology Program and Platform, incorporating small-molecule structure and screening data from the Broad Institute's high-throughput screening facilities.

  • Differentiation Map Portal (DMAP)

    The Differentiation Map Portal (DMAP) contains data and publications used in the study of a differentiation map of hematopoiesis.

  • Genome Data Analysis Center (GDAC)

    On behalf of The Cancer Genome Atlas, the Broad Genome Data Analysis Center designs and operates scientific data and analysis pipelines which pump terabyte-scale genomic datasets through scores of quantitative algorithms, in the hope of accelerating the understanding of cancer.

  • ICBP Data & Analysis Portal

    The ICBP Data and Analysis Portal serves as an information hub of the ICBP program enabling resource sharing, annotation, and data integration and analysis. The portal provides access to datasets, analysis tools, visualizations, and other resources produced by the ICBP Centers for Cancer Systems Biology.

  • Integrative Genomics Portal (IGP)

    The Broad Integrative Genomics Portal allows the sharing (both private and public) of annotated and integrated genomic datasets. Funded by the Starr consortium, the portal provides both data analyses and visualizations.

  • Medulloblastoma Portal

    A collection of recent publications aimed at identifying the drivers of medulloblastoma, such as mutations or chromosome alterations, which will enable development of more effective and and less toxic targeted therapies.

  • Multiple Myeloma Genomics Portal (MMGP)

    The Multiple Myeloma Genomics Portal (MMGP) provides access to and analysis of the MMGP portal data sets. These include the MMRC-funded reference collection of paired aCGH and gene expression data as well as several additional public multiple myeloma datasets.

  • Project Achilles Data Portal

    Project Achilles is a systematic effort aimed at identifying and cataloging genetic vulnerabilities across hundreds of genomically characterized cancer cell lines. The project uses a genome-wide shRNA library to silence individual genes and identify those genes that affect cell survival. Large-scale functional screening of cancer cell lines provides a complementary approach to those studies that aim to characterize the molecular alterations (mutations, copy number alterations, etc.) of primary tumors, such as The Cancer Genome Atlas. The overall goal of the project is to link cancer genetic dependencies to their molecular characteristics in order to Identify molecular targets and guide therapeutic development.